Early Stage Finding of an Immune-Enhanced Genetic Subtype of Nonsmall Cell Lung Cancer Related with T-Cell Depletion

Figure 7

TIDE analysis that predicts the efficacy of immunotherapy across subtypes. (a) The KM curve depicting the TIDE analysis prediction responses in RNAseq. (b) A comparison of the TIDE prediction analysis responses for the two different RNAseq immune subtypes, including the T cell dysfunction score, the T cell exclusion score, and the TIDE score of RNAseq samples. (d) The GSE is the outcome of the KM curve for the TIDE prediction study. (e) A comparison of the findings of the TIDE prediction study performed on the two immunological subtypes of GSE. (f) T cell dysfunction score, T cell exclusion score, and TIDE score of GSE samples. Ns indicates that there is no significant difference between the three scores. less than 0.01, less than 0.001, and less than 0.0001.

(a)

(b)

(c)

(d)

(e)

(f)